IL127366A0 - Insulin preparations containing NaCl - Google Patents

Insulin preparations containing NaCl

Info

Publication number
IL127366A0
IL127366A0 IL12736697A IL12736697A IL127366A0 IL 127366 A0 IL127366 A0 IL 127366A0 IL 12736697 A IL12736697 A IL 12736697A IL 12736697 A IL12736697 A IL 12736697A IL 127366 A0 IL127366 A0 IL 127366A0
Authority
IL
Israel
Prior art keywords
insulin preparations
preparations containing
containing nacl
insulin
nacl
Prior art date
Application number
IL12736697A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127366(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL127366A0 publication Critical patent/IL127366A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12736697A 1996-06-20 1997-06-19 Insulin preparations containing NaCl IL127366A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en) 1996-06-20 1997-06-19 INSULIN PREPARATIONS CONTAINING NaCl

Publications (1)

Publication Number Publication Date
IL127366A0 true IL127366A0 (en) 1999-10-28

Family

ID=8096378

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12736697A IL127366A0 (en) 1996-06-20 1997-06-19 Insulin preparations containing NaCl
IL127366A IL127366A (en) 1996-06-20 1998-12-02 Insulin preparations containing halogenide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL127366A IL127366A (en) 1996-06-20 1998-12-02 Insulin preparations containing halogenide

Country Status (21)

Country Link
EP (1) EP0921812B2 (de)
JP (2) JP4404380B2 (de)
KR (1) KR100451778B1 (de)
CN (1) CN1120019C (de)
AT (1) ATE208208T1 (de)
AU (1) AU720484B2 (de)
BR (1) BR9709845B1 (de)
CA (1) CA2258097C (de)
CZ (1) CZ297937B6 (de)
DE (1) DE69708121T3 (de)
DK (1) DK0921812T4 (de)
ES (1) ES2167751T5 (de)
HU (1) HU228094B1 (de)
IL (2) IL127366A0 (de)
NO (1) NO324430B1 (de)
PL (1) PL189964B1 (de)
PT (1) PT921812E (de)
RU (1) RU2182015C2 (de)
UA (1) UA49890C2 (de)
WO (1) WO1997048414A1 (de)
ZA (1) ZA975470B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
ATE259653T1 (de) * 1998-11-18 2004-03-15 Novo Nordisk As Stabile wässrige insulinzubereitungen ohne phenol und kresol
JP2002535287A (ja) * 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
AU4937699A (en) * 1999-04-05 2000-10-23 Olga Evgenievna Kolesova Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
EP1523993A1 (de) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptidzusammensetzungen mit verbesserter Stabilität
ES2236010T3 (es) * 1999-12-16 2005-07-16 Eli Lilly And Company Composiciones de polipeptidos con estabilidad mejorada.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2581798A1 (en) 2004-10-05 2006-04-13 Petter Lybeck A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2013368990B2 (en) * 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
AU2015205620A1 (en) * 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DE122006000015I1 (de) * 1993-06-21 2006-06-29 Novo Nordisk As Asp-B28-Insulinkristalle
AU682061B2 (en) * 1993-09-17 1997-09-18 Novo Nordisk A/S Acylated insulin
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations

Also Published As

Publication number Publication date
CA2258097C (en) 2011-02-08
CN1120019C (zh) 2003-09-03
ES2167751T5 (es) 2012-03-30
BR9709845A (pt) 1999-08-10
JP4404380B2 (ja) 2010-01-27
CZ395698A3 (cs) 1999-05-12
JP2009235075A (ja) 2009-10-15
DE69708121D1 (de) 2001-12-13
DE69708121T3 (de) 2012-05-16
NO324430B1 (no) 2007-10-15
AU3253697A (en) 1998-01-07
HUP9904031A2 (hu) 2000-04-28
HU228094B1 (en) 2012-10-29
AU720484B2 (en) 2000-06-01
PL330763A1 (en) 1999-05-24
DE69708121T2 (de) 2002-08-01
NO985981D0 (no) 1998-12-18
ATE208208T1 (de) 2001-11-15
DK0921812T4 (da) 2012-04-02
CN1222083A (zh) 1999-07-07
CA2258097A1 (en) 1997-12-24
NO985981L (no) 1998-12-18
HUP9904031A3 (en) 2000-10-30
CZ297937B6 (cs) 2007-05-02
EP0921812B2 (de) 2011-12-21
RU2182015C2 (ru) 2002-05-10
DK0921812T3 (da) 2002-02-11
IL127366A (en) 2007-07-04
KR100451778B1 (ko) 2004-11-16
PT921812E (pt) 2002-04-29
PL189964B1 (pl) 2005-10-31
ES2167751T3 (es) 2002-05-16
KR20000022031A (ko) 2000-04-25
BR9709845B1 (pt) 2008-11-18
EP0921812A1 (de) 1999-06-16
WO1997048414A1 (en) 1997-12-24
JP2000513344A (ja) 2000-10-10
UA49890C2 (uk) 2002-10-15
EP0921812B1 (de) 2001-11-07
ZA975470B (en) 1997-12-22

Similar Documents

Publication Publication Date Title
IL127366A0 (en) Insulin preparations containing NaCl
AU635358B2 (en) Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
ATE369146T1 (de) Insulinpreparation mit mannitol
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
IL142011A0 (en) Stable concentrated insulin preparations for pulmonary delivery
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
EP0573423A4 (en) Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
NO20012249L (no) Faststoffsammensetning inneholdende D-mannitol og cerivastatin samt anvendelse av faststoffsammensetning forfremstilling av farmasöytisk preparat
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
AU631334B2 (en) 2-substituted n,n'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them
ATE196914T1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
ES2152315T3 (es) Xamoneline tartrato.
DE69401030T2 (de) Aerosolformulierung enthaltend Fusafungin
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
FR2696926B1 (fr) Prothèse totale du genou du type intracondylienne.
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
DE58902178D1 (en) Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.
Greer Effects of NaCl on tobacco callus cultures
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed